systemat
effort
identifi
candid
repurpos
drug
broadspectrum
hostori
antitoxin
countermeasur
screen
member
john
hopkin
clinic
compound
librari
jhccl
agent
previous
approv
drug
us
food
drug
administr
abil
reduc
lethal
cell
treat
either
bacillu
anthraci
lethal
toxin
diphtheria
toxin
fig
toxin
chosen
mechan
underli
pathogen
well
understood
dispar
percent
cell
use
assay
normal
undergo
cell
death
determin
mtt
assay
within
hour
exposur
anthrax
lethal
toxin
diphtheria
toxin
respect
experiment
condit
employ
hit
screen
defin
event
cell
expos
compound
concentr
increas
cell
surviv
least
standard
deviat
hit
rate
surviv
control
cell
treat
either
toxin
cytotox
cell
absenc
toxin
event
defin
multiplex
hit
interf
cell
kill
toxin
fig
five
multiplex
hit
identifi
test
anthrax
toxin
diphtheria
toxin
enter
cytoplasm
acidifi
wherea
diphtheria
toxin
adp
ribosyl
transferas
anthrax
toxin
proteas
cleav
host
mapkk
fig
identifi
agent
inactiv
host
protein
exploit
toxin
focus
hit
inhibit
mechanist
differ
act
anthrax
diphtheria
toxin
order
elucid
hosttarget
inhibit
drug
use
anthrax
toxin
host
cellular
pathway
deliv
anthrax
toxin
cytoplasm
one
best
understood
fig
anthrax
lethal
toxin
exotoxin
protein
complex
consist
protect
antigen
pa
lethal
factor
lf
act
collect
damag
host
pa
kda
cellular
receptorbind
protein
combin
pa
lf
lf
kda
zinc
metalloproteas
cleav
ntermin
substrat
dock
site
mitogenactiv
protein
kinas
kinas
prevent
passag
signal
cjun
ntermin
kinas
intox
cell
begin
bind
host
cellular
receptor
capillari
morphogenesi
protein
tumor
endotheli
marker
integrin
beta
bound
host
furin
cleav
kda
fragment
nterminu
thu
activ
kda
protein
follow
activ
form
heptam
bind
toxin
undergo
clathrinmedi
endocytosi
decreas
endosom
ph
induc
format
endosom
membran
pa
channel
lf
transloc
pa
pore
transport
lysosom
rapid
pa
shown
induc
process
autophagi
wherebi
autophagosom
encapsul
endosom
facilit
deliveri
lf
lysosom
protein
cathepsin
b
necessari
autophag
flux
wherebi
lf
deliv
intralumen
vesicl
autophagosomeencapsul
multivesicular
late
endosom
cytoplasm
back
fusion
observ
five
compound
inhibit
anthrax
diphtheria
toxin
two
compound
structur
relat
chloroquin
amodiaquin
two
antimalari
drug
chloroquin
cq
amodiaquin
aq
observ
complet
protect
host
cell
anthrax
toxin
kill
toxin
kill
assay
fig
howev
assay
show
unlik
aq
cq
moder
abil
protect
cell
lfpa
mediat
kill
fig
interestingli
none
quinolinecontain
antimalari
compound
cinchonin
primaquin
quinidin
jhccl
activ
supplementari
fig
oral
administr
aq
rapidli
absorb
undergo
fast
extens
metabolis
hepatocyt
cytochrom
enzym
aq
metabolit
desethylamodiaquin
deaq
main
activ
metabolit
test
abil
deaq
reduc
anthrax
toxin
mediat
cellular
kill
observ
like
aq
deaq
abl
reduc
toxinmedi
cytotox
fig
sinc
aq
metabolit
deaq
protect
host
cell
anthrax
toxin
kill
evalu
efficaci
aq
therapeut
agent
anthrax
toxin
intox
spraguedawley
rat
anim
inject
intraven
lethal
dose
anthrax
toxin
intraven
coinject
aq
mgkg
aq
dose
select
base
fda
approv
aq
dose
anim
receiv
lethal
dose
anthrax
toxin
without
aq
die
within
minut
post
intox
fig
administr
aq
mgkg
save
rat
anim
group
display
classic
sign
undergon
toxin
challeng
ataxia
lethargi
hyperpnea
tachypnea
rat
challeng
anthrax
toxin
treat
aq
mgkg
surviv
without
display
toxinassoci
symptom
fig
order
identifi
step
aq
inhibit
lfpamedi
lethal
assess
process
mediat
cellular
entri
toxin
toxininduc
pyroptosi
presenc
absenc
drug
activ
occur
late
lfpa
intox
monitor
use
fluoresc
probe
flica
probe
specif
bind
activ
observ
high
level
activ
upon
lfpa
treatment
absenc
aq
activ
detect
aqtreat
cell
challeng
anthrax
toxin
fig
result
show
aq
inhibit
cytotox
upstream
activ
activ
lf
late
step
pyroptosi
depend
lf
catalyt
determin
whether
aq
block
proteolysi
cellular
mapkk
lf
assess
cleavag
immunoblot
cleav
lfpa
treat
cell
treatment
aq
complet
prevent
effect
fig
result
show
aq
inhibit
either
cytotox
upstream
mapkk
cleavag
block
lf
directli
order
test
whether
aq
inhibit
enzymat
activ
lf
use
fluoresc
reson
energi
transfer
fret
base
assay
peptid
contain
cleavag
site
lf
fluorogen
dabcyl
group
nterminu
fitc
quench
group
cterminu
use
lf
substrat
vitro
assay
cleavag
lf
fluoresc
emit
dabcyl
increas
fig
test
abil
aq
inhibit
proteolyt
activ
lf
use
fret
presenc
known
small
molecul
inhibitor
lf
surfen
emiss
nm
seen
fig
absenc
chemic
inhibitor
lf
cleav
mapkk
peptid
fluoresc
emiss
observ
fig
similar
emiss
nm
observ
lf
abl
cleav
mapkk
peptid
presenc
aq
show
aq
block
proteolyt
activ
lf
aqtreat
cell
found
less
sensit
treatment
pa
fig
e
hybrid
toxin
contain
pa
bind
site
lf
well
toxin
domain
deriv
p
aeruginosa
exotoxin
wide
use
lf
surrog
kill
cell
differ
result
along
data
strongli
suggest
aq
interfer
pa
mediat
toxin
entri
order
lf
reach
cytosol
must
bind
host
cell
receptor
cleav
furin
heptamer
prepor
form
bind
lf
proceed
lowph
endosom
paheptam
undergo
aciddepend
conform
chang
prepor
hostcel
bind
pa
proteolyt
cleavag
monitor
immunoblot
presenc
absenc
aq
observ
aq
block
bind
cell
block
proteolyt
process
pa
gener
fig
inabl
aq
block
activ
host
furin
cleavag
consist
observ
aq
equal
reduc
sensit
host
cell
lf
lf
treatment
supplementari
fig
result
indic
aq
block
intox
step
downstream
pa
bind
assembl
hostcel
surfac
cq
previous
shown
prevent
endosom
sinc
aq
structur
similar
cq
test
whether
aq
neutral
anthrax
toxin
induc
endosom
acidif
use
lysosensor
green
probe
acid
organel
cell
lysosensor
green
fluoresc
dye
use
track
acid
organel
cell
neutral
compart
visual
loss
punctatefluoresc
structur
absenc
aq
patreat
cell
display
lysosensor
fluoresc
aq
markedli
decreas
cellassoci
lysosensor
fluoresc
fig
result
predict
aq
may
block
abil
pa
either
access
acidifi
endosom
form
pa
pore
known
pore
format
pa
result
exposur
acid
ph
within
endosom
resist
dissoci
sd
run
oligom
surprisingli
treatment
cell
aq
result
higher
rather
lower
abund
sdsresist
paoligom
compar
cell
treat
pa
fig
similar
observ
report
ha
et
show
inhibit
host
lysosom
cathepsin
b
unrel
small
molecul
result
elev
accumul
pa
pore
late
endosom
ii
inabl
lf
releas
late
endosom
cytoplasm
iii
result
reduct
cellular
sensit
lfpa
upon
format
sdsresist
pore
acid
endosom
pa
pore
transport
lysosom
rapid
ha
et
al
show
cathepsin
b
mediat
fusion
lysosom
endosom
fusion
necessari
releas
lf
endosom
order
gain
insight
mechan
aqmedi
protect
cell
anthrax
toxin
kill
test
whether
aq
inhibit
cathepsin
b
proteas
activ
purifi
human
cathepsin
b
use
fret
assay
observ
aq
deaq
directli
inhibit
cathepsin
b
activ
dose
depend
manner
without
drug
preincub
drug
concentr
use
cellular
experi
fig
test
whether
aq
inhibit
cathepsin
b
cell
observ
cell
pretreat
aq
deaq
hour
lost
cathepsin
b
enzymat
activ
dose
depend
manner
supplementari
fig
addit
test
abil
aq
inhibit
cathepsin
b
activ
protein
lysat
cell
expos
drug
prior
lysi
observ
aq
deaq
inhibit
cathepsin
b
activ
supplementari
fig
determin
addit
drug
cathepsin
b
reaction
chang
ph
ph
reaction
buffer
cathepsin
b
experi
observ
cq
metabolit
desethylchloroquin
decq
weaker
inhibitor
cathepsin
b
activ
fig
figur
correspond
phenotyp
data
seen
fig
interact
aq
cathepsin
b
probe
use
satur
transfer
differ
nmr
spectroscopi
std
techniqu
power
labelfre
ligandobserv
tool
studi
molecular
interact
std
reli
transfer
select
satur
excit
protein
atom
atom
locat
bound
ligand
two
spectra
protein
signal
select
satur
reson
isat
anoth
signal
satur
reson
ligand
bind
evid
differ
spectrum
isat
bind
occur
signal
ligand
affect
figur
show
spectrum
mm
aq
presenc
cathepsin
b
ligand
protein
molar
ratio
correspond
std
differ
spectrum
presenc
aq
signal
differ
spectrum
clearli
indic
bind
enzym
inspect
atomspecif
effect
provid
insight
mode
bind
atom
quinolin
backbon
display
largest
reduct
intens
suggest
close
proxim
cathepsin
b
fig
atom
exhibit
std
effect
respect
contrast
methylen
proton
modestli
affect
suggest
complex
locat
distal
hydrogen
atom
protein
interestingli
sever
atom
phenol
ring
display
substanti
std
effect
suggest
near
protein
consist
lower
biolog
activ
aq
analog
remov
phenol
ring
fig
supplementari
fig
import
aq
quinolin
ring
reveal
std
also
compat
crystal
structur
cathepsin
b
bound
nitroxolin
small
molecul
contain
quinolin
moieti
interact
extens
upon
observ
aq
protect
cell
anthrax
diphtheria
toxin
hypothes
aq
deaq
might
also
abl
inhibit
entri
ebola
viru
ebola
viru
among
virus
requir
low
endosom
well
host
cathepsin
b
membran
fusion
infect
host
cell
fact
aq
cq
recent
report
inhibit
ebola
viru
pathogen
retest
aq
cq
abil
inhibit
ebola
viru
abund
infect
hela
cell
visual
infect
cell
use
immunestain
addit
test
abil
metabolit
deaq
decq
inhibit
eboa
viru
propag
cultur
cell
vitro
test
aqmedi
inhibit
viral
propag
compar
infect
ebola
viru
kikwit
moi
without
drug
hour
detect
infect
cell
immunostain
complet
antiebolaglycoprotein
antibodi
aq
deaq
effect
inhibit
propag
ebola
viru
hela
cell
low
rang
tabl
aq
deaq
respect
cq
decq
hela
respect
data
show
deaq
efficaci
inhibit
ebola
propag
compar
decq
similar
result
obtain
test
aq
cq
deaq
decq
abil
inhibit
ebola
viru
primari
human
cell
line
supplementari
tabl
result
confirm
antivir
effect
aq
relat
effect
host
cell
cycl
cellular
prolifer
life
cycl
ebola
viru
cultur
host
cell
hour
clearli
evalu
effect
aq
deaq
singl
viral
life
cycl
compar
inhibitori
effect
drug
hour
ebola
viru
infect
cell
observ
aq
deaq
least
two
time
potent
h
infect
compar
h
time
secondari
round
infect
occur
possibl
slightli
decreas
antivir
efficaci
aq
deaq
tabl
addit
anthrax
diphtheria
ebola
pathogen
agent
sar
venezuelan
equin
enceph
viru
veev
rabi
junin
chikungunya
clostridium
difficil
toxin
enter
cytoplasm
endosom
requir
acidif
endosom
demonstr
pathogen
agent
inhibit
aq
respect
vitro
cellular
assay
tabl
supplementari
fig
also
test
abil
deaq
inhibit
pathogen
junin
chikungunya
virus
observ
deaq
inhibit
two
virus
similar
aq
supplementari
tabl
pathogen
agent
includ
cholera
pseudomona
aeruginosa
exotoxin
polioviru
herp
simplex
viru
transport
retrograd
fashion
endoplasm
reticulum
er
retrotransloc
cytoplasm
host
erassoci
degrad
observ
cytotox
mediat
pathogen
block
aq
tabl
supplementari
fig
c
addit
inabl
aq
inhibit
cholera
pseudomona
toxin
adprybosyltransferas
suggest
aq
advers
effect
diphtheria
toxin
fig
also
adprybosyltransferas
occur
inhibit
host
cathepsin
b
anoth
group
pathogen
enter
cytoplasm
way
reli
acidif
endosom
includ
human
respiratori
syncyti
determin
aq
reduc
pathogen
virus
tabl
data
support
conclus
aq
inhibit
entri
toxin
cytoplasm
acidifi
endosom
discoveri
develop
novel
drug
biolog
threat
agent
bacillu
anthraci
ebola
viru
import
concern
worldwid
shown
aq
broadspectrum
drug
could
appli
rapidli
cure
biolog
emerg
caus
sever
identifi
pathogen
fig
exampl
current
ebola
crisi
alreadi
kill
peopl
repurpos
compound
wellestablish
safeti
pharmacokinet
well
proven
highvolum
gmp
way
therapi
test
deploy
time
protect
million
peopl
three
hardesthit
west
african
countri
help
address
ebola
crisi
prepar
manuscript
commun
discoveri
san
msf
doctor
without
border
encourag
explor
whether
administr
aq
west
african
countri
hit
ebola
epidem
associ
reduc
mortal
due
ebola
infect
msf
conduct
studi
observ
administr
aq
provid
substanti
protect
ebola
mortal
reduc
mortal
risk
studi
msf
acknowledg
author
studi
http
wwwyoutubecomwatch
seen
current
ebola
epidem
human
host
coexpos
numer
deadli
pathogen
thu
infect
individu
need
take
numer
countermeasur
sideeffect
protect
multipl
infecti
organ
therefor
therapi
capabl
inhibit
multipl
pathogen
need
broadspectrum
antipathogen
drug
capabl
simultan
inhibit
numer
unrel
pathogen
could
develop
target
host
protein
commonli
exploit
pathogen
work
show
aq
inhibit
host
target
rather
pathogen
make
aq
hostori
broadspectrum
antimicrobi
less
like
circumv
pathogen
mutat
lead
microbi
resist
countermeasur
aq
discov
parkedavi
approv
fda
antimalari
late
earli
trade
name
camoquin
aq
current
model
list
essenti
medicin
today
aq
recommend
frontlin
antimalari
therapi
combin
artemisinin
aq
belong
quinolin
antimalari
review
aq
inhibit
plasmodium
falciparum
phosphoethanolamin
methyltransferas
enzym
found
malari
parasit
report
aq
also
bind
block
function
host
cathepsin
b
protein
thu
entri
key
pathogen
cytoplasm
sinc
aq
use
past
year
safeti
pharmacokinet
profil
well
known
exampl
determin
oral
administr
healthi
subject
aq
quickli
absorb
biotransform
main
activ
form
deaq
turn
slowli
elimin
termin
halflif
day
avail
pk
valu
aq
allow
us
compar
vitro
data
valu
test
pathogen
inhibit
aq
deaq
low
rang
importantli
known
cmax
valu
maxim
amount
drug
blood
oral
administr
deaq
human
low
compar
deaq
valu
found
vitro
test
pathogen
suggest
possibl
achiev
antipathogen
effect
aq
dose
blood
oral
administ
aq
toxin
purchas
list
biolog
laboratori
kind
gift
leppla
nation
institut
allergi
infecti
diseasesn
institut
health
bethesda
md
fdaapprov
drug
librari
compris
drug
purchas
john
hopkin
titl
john
hopkin
clinic
compound
librari
jhccl
version
drug
arriv
mm
stock
solut
seal
microtit
plate
made
use
dmso
water
solvent
drug
array
plate
screen
stock
concentr
mm
librari
store
use
prior
use
librari
drug
thaw
compound
determin
compound
interest
isol
reproduc
mm
solut
amodiaquin
chloroquin
cinchonin
primaquin
quinidin
purchas
sigmaaldrich
st
loui
mo
usa
drug
prepar
mm
use
dmso
solvent
desethylamodiaquin
desethylchloroquin
purchas
toronto
research
chemic
inc
antitubulin
antipa
antibodi
purchas
santa
cruz
biotechnolog
purifi
human
cathepsin
b
protein
use
nmr
experi
purchas
acrobiosystem
mous
macrophag
cell
maintain
dmem
sigmaaldrich
supplement
fb
bioexpress
penicillin
streptomycin
cell
per
well
seed
plate
hour
assay
drug
librari
screen
assay
mm
drug
ad
cellcontain
media
achiev
compound
per
well
cell
treat
compound
hour
challeng
anthrax
toxin
final
toxin
concentr
cell
treat
toxin
drug
hour
rodent
cell
resist
diphtheria
toxin
human
melanoma
cell
line
use
diphtheria
toxin
screen
cell
treat
hour
determin
cell
viabil
bromid
mtt
assay
perform
cell
viabil
shown
percentag
surviv
cell
obtain
rel
cell
treat
dmso
drug
test
plate
reaction
volum
per
well
contain
mm
hepe
ph
mapkkid
conjug
dabyl
fitc
list
biolog
laboratori
inc
jhccl
compound
reaction
initi
ad
lf
final
concentr
kinet
measur
obtain
everi
sec
min
use
fluoresc
plate
reader
excit
emiss
wavelength
nm
nm
respect
cutoff
wavelength
nm
cell
seed
plate
densiti
cellswel
toxin
treatment
variou
concentr
lf
combin
fix
concentr
pa
ngml
ad
well
cell
incub
h
cell
viabil
measur
mtt
assay
toxin
treatment
experi
cell
pretreat
variou
concentr
drug
treat
constant
concentr
c
difficil
toxin
b
ngml
p
aeruginosa
exotoxin
ngml
cholera
toxin
hour
surviv
measur
mtt
assay
data
point
shown
mtt
assay
indic
mean
sd
valu
obtain
triplic
assay
done
repres
experi
least
three
experi
routin
carri
cell
pretreat
mm
aq
hour
follow
pretreat
cell
expos
mgml
pa
lf
two
hour
presenc
aq
cell
wash
cold
pb
lyse
ripa
buffer
contain
proteas
inhibitor
mixtur
roch
cell
lysat
quantifi
use
bca
protein
quantif
kit
pierc
load
onto
denatur
gel
criterion
xt
precast
gel
biorad
electrophoresi
sever
hour
gel
transfer
overnight
nitrocellulos
membran
membran
probe
anti
tubulin
antibodi
quantit
western
blot
analys
band
accomplish
use
versadoc
instrument
biorad
odyssey
infrar
imag
system
licor
bioscienc
cell
pretreat
aq
describ
h
either
pa
bind
pa
intern
assay
cell
expos
pa
h
bind
assay
h
intern
assay
cell
wash
pb
solut
three
time
lyse
ripa
buffer
contain
proteas
inhibitor
mixtur
roch
western
blot
analysi
perform
use
antipa
antibodi
antitubulin
monoclon
antibodi
sigmaaldrich
chemiluminesc
band
rel
intens
reveal
use
versadoc
instrument
biorad
cell
treat
aq
h
addit
ngml
lfpa
addit
h
fam
caspas
assay
kit
obtain
immunochemistri
technolog
llc
flica
reagent
ad
h
flica
fluoresc
visual
follow
cell
wash
three
time
pb
fix
wtvol
paraformaldehyd
examin
fluoresc
microscop
b
leica
cell
treat
aq
h
addit
ngml
pa
addit
hour
stain
lysosensor
green
min
cell
wash
fluoresc
visual
follow
cell
fix
wtvol
paraformaldehyd
examin
fluoresc
microscop
b
leica
cathepsin
b
activ
total
cell
lysat
determin
use
innozym
cathepsin
b
activ
assay
kit
emd
milipor
perform
accord
manufactur
instruct
cathepsin
b
activ
cellular
lysat
test
follow
way
cell
untreat
drug
lyse
equal
amount
cathepsin
b
contain
protein
lysat
ad
substrat
solut
emd
milipor
without
aq
cq
deaq
decq
concentr
cellular
cathepsin
b
activ
without
drug
test
pretreat
cell
drug
hour
follow
lyse
cell
test
cathepsin
b
activ
fluoresc
label
substrat
activ
purifi
human
cathepsin
b
mix
without
drug
without
preincub
detect
fluoresc
label
substrat
fluoresc
intens
indic
cathepsin
b
activ
measur
excit
wavelength
nm
emiss
wavelength
nm
molecular
devic
spectra
max
plu
rat
studi
perform
explora
biolab
san
diego
ca
follow
institut
anim
care
use
committe
iacuc
approv
protocol
five
male
spraguedawley
rat
g
charl
river
per
group
use
toxin
mixtur
prepar
group
mix
lf
pa
mgkg
amodiaquin
volum
per
rat
rat
monitor
sign
clinic
ill
death
day
challeng
std
experi
perform
use
bruker
avanc
spectromet
equip
cryogen
probe
puls
scheme
employ
excit
sculpt
gradient
ms
spin
lock
filter
suppress
signal
origin
water
protein
signal
irradi
power
hz
appli
onreson
ppm
offreson
ppm
total
satur
time
spectra
collect
interleav
manner
account
tempor
fluctuat
separ
control
experi
perform
use
sampl
cathepsin
b
amodiaquin
confirm
select
satur
std
spectra
acquir
scan
k
data
point
use
spectral
width
hz
center
hz
experi
perform
deuter
tri
buffer
mm
mm
nacl
ph
supplement
sampl
use
std
measur
contain
mm
mm
cathepsin
b
amodiaquin
respect
std
nmr
data
process
analyz
use
topspin
softwar
bruker
billerica
std
effect
calcul
accord
formula
astd
isat
isat
intens
amodiaquin
signal
record
without
satur
protein
respect
procedur
viral
experi
describ
supplement
materi
method
specif
infect
hela
cell
ebola
done
use
ebola
viru
kikwit
moi
calcul
cellswel
assum
one
complet
round
replic
hela
cell
hr
cell
seed
cell
incub
viru
h
infect
termin
fix
sampl
formalin
solut
immunostain
use
visual
infect
cell
cell
treat
antigp
specif
monoclon
antibodi
dilut
follow
antimous
igg
conjug
thermo
dilut
block
buffer
contain
bsa
pb
nuclei
stain
biostatu
dilut
pb
buffer
imag
acquir
opera
imag
instrument
perkin
elmer
use
air
object
four
imageswel
acquir
analyz
use
pe
acapella
algorithm
cite
articl
zilbermintz
l
et
al
identif
agent
effect
multipl
toxin
virus
hostori
cell
target
sci
rep
doi
